Jan 01,2021

Time in range–A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study

The availability of easily accessible continuous glucose monitoring (CGM) metrics can improve glycemic control in diabetes, and they may even become a viable alternative to hemoglobin A1c (HbA1c) laboratory tests in the next years. The REALISM-T1D study (REAl-Life glucoSe Monitoring in Type 1 Diabetes) was aimed at contributing, with real-world data, to a deeper understanding of these metrics, including the time in range (TIR)–HbA1c relationship, to facilitate their adoption by diabetologists in everyday practice.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 11,2021

Teladoc Health and Dexcom Bring CGM Technology and Personalized Insights to People with Type 2 Diabetes at No Cost

Teladoc Health, Inc. and DexCom, Inc. today announced that joint Livongo for Diabetes and Dexcom members will now receive CGM-powered insights, a new set of features and reports that help members more easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 01,2021

Multilevel clustering approach driven by continuous glucose monitoring data for further classification of type 2 diabetes

Mining knowledge from continuous glucose monitoring (CGM) data to classify highly heterogeneous patients with type 2 diabetes according to their characteristics remains unaddressed. A refined clustering method that retrieves hidden information from CGM data could provide a viable method to identify patients with different degrees of dysglycemia and clinical phenotypes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2021

ASCENSIA DIABETES CARE TAKES OVER DISTRIBUTION OF EVERSENSE® XL CONTINUOUS GLUCOSE MONITORING SYSTEM IN SELECTED EUROPEAN MARKETS

Ascensia Diabetes Care, a leading global diabetes care company, has today entered the continuous glucose monitoring market in Europe as it takes over the distribution of Senseonics’ Eversense® XL, the world’s first and only long-term implantable continuous glucose monitoring (CGM) system, in selected European markets. This follows the signing of a commercialization and distribution agreement in August 2020 with Senseonics Inc., which enables Ascensia to offer Eversense® products, over a 5-year period, in selected countries. As part of this agreement, Ascensia has today taken over distribution of Eversense® XL in Germany, Switzerland, Italy, Spain, The Netherlands and Poland. In the US, Ascensia is already providing sales support for the Eversense® 90-day implantable CGM system, and will take over increased commercialization from April 1, 2021.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 22,2021

Eat this, exercise now; new personalized software predicts and helps prevent blood sugar spikes

Enter software by January AI, a four-year-old, subscription-based startup that in November began providing personalized nutritional and activity-related suggestions to its customers based on a combination of food-related data the company has quietly amassed over three years, and each person’s unique profile, which is gleaned over that individuals’s first four days of using the software.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 11,2021

Nemaura Medical Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device

Nemaura Medical, a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces its submission to G-BA (Gemeinsamer Bundesausschuss) for approval of sugarBEAT®, the Company’s non-invasive, daily wear, continuous glucose monitoring device.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 18,2021

Initiating our First Clinical Study of our Continuous Glucose Monitoring Sensor

GROUND-BREAKING SUBCUTANEOUS SENSOR AIMS TO CONTINUOUSLY MONITOR MULTIPLE METABOLITES INCLUDING KETONES IN PEOPLE LIVING WITH DIABETES

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 05,2021

Welldoc and Dexcom Expand Strategic Partnership to Integrate Platforms and Offer Integrated Type 2 Diabetes Management Solution

Welldoc and Dexcom today announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes. Welldoc will offer its BlueStar® digital health solution and the Dexcom G6 CGM system as a single platform offering for select employers and health systems, beginning with a Fortune 100 company.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 15,2021

Effect of Hypoglycemia on Heart Rate Variability in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia

People with impaired awareness of hypoglycemia (IAH) are at elevated risk of severe, potentially hazardous, hypoglycemia and would benefit from a device alerting to hypoglycemia. Heart rate variability (HRV) changes with hypoglycemia due to sympathetic activity. Since IAH is associated with suppressed sympathetic activity, we investigated whether hypoglycemia elicits a measurable change in HRV in patients with T1D and IAH.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 15,2021

A Modified CGM Algorithm Enhances Data Availability While Retaining iCGM Performance

The algorithm for the Dexcom G6 CGM System was enhanced to retain accuracy while reducing the frequency and duration of sensor error. The new algorithm was evaluated by post-processing raw signals collected from G6 pivotal trials (NCT02880267) and by assessing the difference in data availability after a limited, real-world launch.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM